In this week’s news: Recipharm Invests in Lab+ Technology at Kaysersberg Facility, helping bolster its sterile filling capabilities. Ardena has invested in almost trebling the size of its Swedish facility, and more.
Global contract development and manufacturing organization (CDMO) Recipharm, has bolstered its sterile filling capabilities by investing in Lab+ technology for low volume blow-fill-seal (BFS) filling at its facility in Kaysersberg, France.
“Recipharm is proud to make such an investment and become one of the first CDMOs in the world to use this type of technology. We look forward to supporting our customers with their packaging compatibility requirements and expanding our BFS offering.”
Ardena has invested in almost trebling the size of its Swedish facility as part of its €35M investment across its European operations. The firm is investing in drug substance manufacturing in Södertälje to increase its capacity. This includes a new production line and a larger preparative High Performance Liquid Chromatography (HPLC), a new lyophilisation unit, and additional large-scale synthesis equipment.
CDMO Micro-Sphere is continuing its expansion and has upgraded at its Swiss site with a further €5M invested in expanding its GMP manufacturing capabilities. Micro-Sphere also announced that its manufacturing license had been renewed with the addition of biologics.
Supply chain experts warn drug shortages aren’t going away any time soon, with supply chain problems one of the key factors. Prices are rising for high-quality drugs like Adderall amoxicillin, but this shortage is even affecting chemotherapy drugs like fludarabine.
CPHI22, one of the biggest events in the pharma industry’s calendar, took place this week – find out all the latest news from the Messe in Frankfurt.
Also in the news
Despite wider global challenges, the contract manufacturing business in 2022 appears to be successfully humming along. New building projects, contracts, and research have been going on throughout the year. Find out what trends experts and analysts have picked up on.
The Lipid Nanoparticles (LNPs) CDMO market is projected to grow at a CAGR of 13.8%, during the period 2022-2030, claims InsightAce Analytic.
Sanofi is selling off a piece of its manufacturing operations in Japan to CDMO Adragos Pharma, although it will continue to have its products manufactured at the site through a new supply agreement.
Global Active Pharmaceutical Ingredients (API) market to reach $264.1 billion by 2027 at a CAGR of 6%.